Aquila’s vision is to evolve with innovation at its core, as a globally-leading pre-clinical contract research organisation (CRO), enhancing drug discovery programmes using cutting-edge research, and facilitating the development of new medicines for the benefit of human health.
The Aquila business model ensures our experienced team is engaged with you, our clients, from an early stage in project discussions, to understand the key scientific questions and study objectives for successful compound development. Drawing on our own extensive experience as well as our academic consultants, projects are designed to optimise drug development programs, in the time frame required.
It is the Aquila mission to apply this foundation across multiple therapeutic areas, developing and delivering highly specialist immuno-oncology and multiplex histology services, bringing innovative academic models e.g. MLRs, exhausted T cell assays and RNAscope, to the heart of drug development in Pharmaceutical and Biotech companies.
Innovation: Creating the right environment, listening to the needs of others, and being responsive, proactive and enthusiastic about the requirements of our clients, combined with the flexibility to nurture creativity and generate new ideas.
Collaboration & Teamwork: Working together with our clients, academic consultants and our team, we achieve mutual growth by sharing knowledge and ideas as well as respecting each other’s opinions.
Motivation: With a clear focus on the benefits of the pre-clinical research that we deliver for our clients, our team comprises highly motivated individuals, with a passion for playing a role in immuno-oncology cancer services, multiplex histology research and translational medicine.